Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 10;38(20):2321-2328.
doi: 10.1200/JCO.19.02806. Epub 2020 May 22.

Multidisciplinary Management of Locoregional Recurrent Breast Cancer

Thomas A Buchholz  1 , Sonia Ali  2 , Kelly K Hunt  3
Affiliations
Review

Multidisciplinary Management of Locoregional Recurrent Breast Cancer

Thomas A Buchholz et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Multidisciplinary Management of Locoregional Recurrent Breast Cancer

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Thomas A. Buchholz

Consulting or Advisory Role: Patient Resource, Breakthrough Chronic Care, Abivax, Burjeel Cancer Center, Genentech, Roche Diagnostics

Patents, Royalties, Other Intellectual Property: I am named on a patent held by MD Anderson Cancer Center as a co-inventor on a method of radiation for patients with cancer with magnetically optimized high-energy electron radiation

Sonia Ali

Speakers' Bureau: Amgen, bioTheranostics, Tesaro

Kelly K. Hunt

Consulting or Advisory Role: Armada Health Care, Merck

Research Funding: Endomagnetics (Inst), Lumicel (Inst)

No other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
An algorithm for multidisciplinary management of patients with locoregional recurrent disease (LRR) after breast-conservation therapy. (*) Breast conservation and re-irradiation of the breast should be used selectively and only for those with favorable tumors (small size, favorable biology, prolonged disease-free interval); consider partial breast radiation if prior whole-breast radiation was previously given. HER2, human epidermal growth receptor 2.
FIG 2.
FIG 2.
An algorithm for multidisciplinary management of patients with locoregional recurrent disease (LRR) after mastectomy. HER2, human epidermal growth receptor 2.
See this image and copyright information in PMC

Comment in

References

    1. Mittendorf EA, Ballman KV, McCall LM, et al. Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer J Clin Oncol 331119–11272015 - PMC - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials Lancet 379432–4442012 - PMC - PubMed
    1. McBride A, Allen P, Woodward W, et al. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment Int J Radiat Oncol Biol Phys 89392–3982014 - PubMed
    1. Yi M, Buchholz TA, Meric-Bernstam F, et al. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning Ann Surg 253572–5792011 - PMC - PubMed
    1. Smith TE, Lee D, Turner BC, et al. True recurrence vs. new primary ipsilateral breast tumor relapse: An analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management Int J Radiat Oncol Biol Phys 481281–12892000 - PubMed